Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines (Q39447473)

12 September 2017

title

Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines (English)

1 reference

12 September 2017

0 references

1 reference

1 reference

D M Collins

1

1 reference

12 September 2017

N O'Donovan

2

1 reference

12 September 2017

P M McGowan

3

1 reference

12 September 2017

F O'Sullivan

4

1 reference

12 September 2017

M J Duffy

5

1 reference

12 September 2017

J Crown

6

1 reference

12 September 2017

publication date

5 November 2011

1 reference

12 September 2017

1 reference

12 September 2017

volume

23

1 reference

12 September 2017

issue

7

1 reference

12 September 2017

page(s)

1788-1795

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

Resistance to Trastuzumab in Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

Self-tolerance of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

Comparison of 5 microplate colorimetric assays for in vitro cytotoxicity testing and cell proliferation assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

Correlation between NK function and response to trastuzumab in metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

Selective targeting of cancer stem cells: a new concept in cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

HER-2, notch, and breast cancer stem cells: targeting an axis of evil

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

HER-2 as a target for breast cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR484

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDR484

1 reference

12 September 2017

1 reference